proposed theory for the development of bmmhial asthma suggests the presence of partial or complete blockage of the beta-adrenergic nervous s y~t e m . l~~ Evidence to support this hypothesis stems from observations that individuals with bronchial astbma have increased sensitivity to beta-adrenergic blocking agents, as well as specific pharmacologic, physiologic and biochemical alteration~.~-~ The present investigation was designed to assess lymphocyte beta-adrenergic receptors in asthma employing binding studies using labeled dihydroalprenolol (DHA).a-11 In addition, the effects of hydrocortisone on DHA binding was also investigated. In asthmatic subjects, specific DHA binding appeared saturable. For all incubation concentrations of DHA, the specific binding was lower in the asthmatic group when compared to the controls. Lymphocytes from normal subjects were divided into two equal aliquots and incubated for 16 hours in phosphate-buffered saline solution with added glucose; 10 n M of hydrocortisone was added to the incubation mixture of one of the aliquots, but not the other. Following incubation, lymphocyte membrane preparations were obtained and binding studies were performed. Figure 3 shows the results of four studies and demonstrates that specific alprenolol binding is significantly greater in lymphocyte membrane protein preincubated with hydrocortisone. The mean value of specific bound alprenolol for hydrocortisone-incubated lymphocytes was approximately four times greater, ie 491 fM/mg protein compared to 116 fM/mg protein in the aliquots not incubated with hydrocortisone (P < 0.05).
In asthmatic subjects, specific DHA binding appeared saturable. For all incubation concentrations of DHA, the specific binding was lower in the asthmatic group when compared to the controls. Lymphocytes from normal subjects were divided into two equal aliquots and incubated for 16 hours in phosphate-buffered saline solution with added glucose; 10 n M of hydrocortisone was added to the incubation mixture of one of the aliquots, but not the other. Following incubation, lymphocyte membrane preparations were obtained and binding studies were performed. Figure 3 shows the results of four studies and demonstrates that specific alprenolol binding is significantly greater in lymphocyte membrane protein preincubated with hydrocortisone. The mean value of specific bound alprenolol for hydrocortisone-incubated lymphocytes was approximately four times greater, ie 491 fM/mg protein compared to 116 fM/mg protein in the aliquots not incubated with hydrocortisone (P < 0.05). theophylline preparations were the predominant therapeutic agents used and administration of beta-adrenergic agonists was limited. This is important since there have been in vftro and in vioo studies which have reported receptor inactivation and/or beta-adrenergic unresponsiveness following the use of beta-adrenergic agonists.
The relationship between lower DHA binding and greater severity of disease noted in the present investigation supports findings of Parker and Smith.ll These investigators reported that there was less increased intracellular cyclic AMP in lymphocytes in response to is* proterenol incubation, in those asthmatic subjects with the more severe and chronic disease.
While the mechanism of action of glucocorticoids in bronchial asthma has long been a subject of controversy, glucocorticoids have been demonstrated to restore or increase responsiveness of tissues and/or cells to catecholamines. The data from the present investigation suggest that this phenomenon may be the result of hydmcorthne causing an increase in the numbers or restoring "sensitivity" to beta-adrenergic receptors available for drug action.
The mechanism to explain differences in DHA binding among asthmatic subjects could include genetic or acquired defects in receptor protein synthesis, receptor protein degradation or change in pools. The clinical SiMcance of the apparent lymphocyte beta-adrenergic receptor abnormality noted in the present investigation needs further study. In patients with bronchial asthma it may reflect a general beta-adrenergic receptor defect. Whether change in receptor activity is dynamic in any individual patient, changing as disease severity varies, needs to be documented. Results from the present investigation suggest that this theory must be given serious consideration. Dr. Turner-Warwick: Did you differentiate your asthmatics in terms of severity of their disease, and did you find any differences between groups in their response to isoproterenol beyond an hour's time? Dr. Brooks: That is a good question. We did differentiate asthmatics in terms of disease severity. AU our patients were stable for a period of months. We assessed severity of disease using clinical and physiologic criteria. We did study one actually ill asthmatic patient. She had decreased alprenolol binding which i n d with her clinical improvement during hospitalization. Serial studies on more patients need to be performed in order to determine the duration, magnitude and significance of these changes in alprenolol binding. Dr. Chick: Were any of you. patients recently on beta adrenergic drugs? Dr. Brooks: This is important since the use of beta adrenergic agonist drugs has been shown to depress in vitro beta-receptor binding. We &ed patients who had either never taken beta adrenergic agonist agents or who had not received them for weeks to months prior to study. Dr. Oren: Is there a dose-response relationship in the effect of glucocorticoid on binding, and is it Merent for different patients, depending on the severity of illness? Dr. Brooks: In oitro studies suggest that this may be true, but this is as yet unstudied. Whether it is same viral product or an effect of the virus particle itself, we do not know. Dr. Chester: Have you had an opportunity to do in dtro studies on leukocytes from non-asthmatic normal subjects during and after viral infections? Dr. Busse: Yes, and they were similarly affected.
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